Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Myelodysplastic Syndromes
Related studies linked through entity extraction aliases.
AVIDA The Vidaza® (Azacitidine) Patient Registry
- Status
- COMPLETED
- Phase
- N/A
Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload
- Status
- COMPLETED
- Phase
- PHASE4
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
- Status
- COMPLETED
- Phase
- PHASE1
Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
- Status
- COMPLETED
- Phase
- NA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Safety, Tolerability, and Efficacy of Deferasirox in MDS
- Status
- COMPLETED
- Phase
- PHASE3
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease
- Status
- UNKNOWN
- Phase
- NA
Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200
- Status
- COMPLETED
- Phase
- PHASE2
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
- Status
- COMPLETED
- Phase
- NA
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
- Status
- TERMINATED
- Phase
- PHASE2
Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- Status
- WITHDRAWN
- Phase
- PHASE2
A Phase II Study of Maintenance With Azacitidine in MDS Patients
- Status
- TERMINATED
- Phase
- PHASE2
Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)
- Status
- UNKNOWN
- Phase
- PHASE2